# Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy

> **NCT02234869** · PHASE4 · WITHDRAWN · sponsor: **Biogen**

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** Interferon Beta
- **DRUG:** BIIB017 (Peginterferon beta-1a)

## Key facts

- **NCT ID:** NCT02234869
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-10
- **Primary completion:** 2017-02
- **Final completion:** 2018-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to a change in Biogen Idec's medical research plans.
- **Last updated:** 2014-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02234869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02234869, "Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02234869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*